future challenges of clinical development; a view from the cro - hani zaki
DESCRIPTION
TRANSCRIPT
12 January 2011
Hani Zaki, MPH, MBASenior Vice President, Late Phase Services
PRA International
Future Challenges of Clinical Development:A View from the CRO
2
Discussion Agenda
• Review Current State– Market Size– Economic Drivers– Market Dynamics– Trends:
• Volume• Geography• Price
• Future Look– Process– Technology– Geography– Regulatory– Privacy– Public Image
3
Clinical Trials By The Numbers
100,838 trials registered on ClinTrial.govas of January 3, 2011
40,998 trials are Pharma based
10,192 are “enrolling”
8,824Interventional
4,633Safety Outcome
20,982 are US based
4
Current Working Relationship
Working Standards, Process, Logistics, Efficiency & Quality Metrics
Resource Shift
5
Global CRO Market
• Current ~$22B and expect $35B through 2015; growing ~8% annually
• Over 1,000 CROs worldwide despite continued consolidation – very fragmented market
• The 5 largest CROs hold >50% of the marketSource: Business Insights
6
CRO Economic Forces
Development Research(Pharma)
Global CRO Business
Arlington Mills, Lawrence, MA in 1907
7
Clinical Research Stock Index
First Clinical Research Index (FCRI). Calculated as the mean average percentagechange from baseline, dividends excluded, adjusted for stock splits. In other words, theindices are not weighted for stock price or market capitalization. Prices are in localcurrencies. Index components may change from time to time based on new listings,mergers and other factors. Components include 11 publicly traded clinical researchstocks: BioClinica (BIOC:US), CMIC (2309:JP), Covance (CVD:US), DatatrakInternational (DATA:US), EPS Co., Ltd. (4282:JP), eResearchTechnology (ERES:US),ICON (ICLR:US), Kendle International (KNDL:US), Medidata (MDSO:US), PAREXELInternational (PRXL:US), and PPD (PPDI:US). In 2010, MDS Pharma Services (MDZ:US)exited the clinical research business, Phase Forward (PFWD:US) was acquired, andEncorium Group (ENCOD:US)’s stock price dropped below $1/share and became toovolatile to include in the index.
Vol. 7, No. 1, January 2011 “Can You Handle the Truth?”Subscribe free at www.firstclinical.com
© 2011 First Clinical ResearchFirst Clinical Research Stock Index (FCRI)
8
Current Market Pressures
GlobalPharma
Pricing Pressures• Governments• Insurers• Patients
Pricing Pressures• Governments• Insurers• Patients
Anemic approvals• 21 in 2010• 25 in 2009• 24 in 2008• 17 in 2007
Anemic approvals• 21 in 2010• 25 in 2009• 24 in 2008• 17 in 2007 IP Protection
&Generic
Competition
IP Protection&
Generic Competition
R&D ROI• Weak pipelines• Investor Demands
R&D ROI• Weak pipelines• Investor Demands
Rising R&D Expense&
Pressure for Efficiency
Rising R&D Expense&
Pressure for Efficiency
Regulatory Pressures• Heightened safety needs• “Real World” Data
Regulatory Pressures• Heightened safety needs• “Real World” Data
9
Patent Expiration 2008-2015$66B in Annual Sales
2011 expirations Total $35.2B
10
Global Pharma ROI
11
Flat R&D Budgets Pharmaceutical R&D as a Share of Sales: 1970 -2008
12
Increasing Cost of Trials
13
Relief in Sight?
Big Firms Poised to Spend Again Saturday, January 1, 2011 By JAMES R. HAGERTY and DANA MATTIOLI
14
Trends in Clinical Trial Volume
• Reflects Pharma-based clinical trials only• Some ClinicalTrials.Gov studies may include missing
fields and may be excluded from data cuts
0
1000
2000
3000
4000
5000
6000
7000
Tri
als
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Clinical Trial Annual Starts 2000 - 2010
Source: CT.gov
15
Pharma Clinical Trial Volume by Phase
Annual Clinical Study Starts by Phase 2000 - 2010
0
500
1000
1500
2000
2500
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Num
ber o
f Stu
dies
Phase I
Phase II
Phase III
Phase IV
Source: CT.gov
16
Post-Approval Shifts in Study Duration
• Average study duration has been decreasing since 2005
• Data suggests a conscious effort to design more efficient studies that are shorter in duration
• Today, 30% of post-approval studies complete in 20 months or less
• 5+ year studies do exist but there are less of them compared to 2005
17
An Early Geographic Trend
18
Geographic Density Shift
Dec 2005
• We are moving East: Asia & CEE• More studies in developing countries
Jan 2011
Source: ClinTrial.gov
19
Post-Approval Geographic Distribution of Sites
• US and EU have had equal distribution and comprise the bulk of sites
• Noteworthy “steady” growth in Asia-Pacific
• Expect the growth trend in Asia to continue through 2010 and beyond
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
2005 2006 2007 2008 2009 2010 (July)
Africa
Asia
Caribbean
Europe
Latin America
North America
Oceania
0
1000
2000
3000
4000
5000
6000
7000
2005 2006 2007 2008 2009 2010 (July)
Africa
Asia
Caribbean
Europe
Latin America
North America
Oceania
Source: ClinTrial.Gov
Source: ClinTrial.Gov
Number of SitesBy Geography
Percent SitesBy Geography
20
Comparative Costs By Geography
21
Trends in Investigator Fees
22
Phase III Cost Per Patient
• Costs increased in all Tx areas across all geographies from 2006 to 2010• Minimal increase was 4% in Eastern EU for patients with musculoskeletal diseases• Largest increase was 43% in Asia for oncology patients
Source: Data Courtesy of TTC
Western EU USA & Canada Middle East
Latin America Eastern EU Asia
23
Some Trends and Needs
Trends Needs
Significant decrease in NME approvals (revenue) at 40x the expense
Development efficiencies
Increasing cost of late phase (II, III, IV) development
New processes, technology & Innovation
Global trials with increasing needs in CEE, Asia, MENA, Africa
Global resources, training, standardization
Fierce competition for study patients Medical informatics and utilization of emerging new data resources
Pharma and Biotech relaying on outsourcing to re-structure expense from fixed to variable
CROs leading change in processes, logistics, metrics, delivery and quality
Future Look
25
Challenge: New Efficiencies
Lead Innovation Lead Efficiency
Lead Delivery Metrics
Lead Quality Metrics
Active Approach: Suppliers Setting New Standards
BalancedCollaboration
GlobalBio-Pharmaceutical
Industry
DiscoveryInnovationLicensing
Supply competitiveness, savings, flexibility, global reach, insight ….Supply competitiveness, savings, flexibility, global reach, insight ….
26
Clinical Trial Costs
Approximate % Value of Clinical Trial Segments
40%
25%
15%
13%
4%3%
Monitoring & Site Management Data ManagementAnalysis & Writing Project ManagementSafety QA
Is this the most
efficient process?
Can we do better to reduce burden? Are we
building effective
partnerships?
27
Challenge: Technology & Innovation
Must be a joint effort between industry, suppliers and regulators
Break from 1970’s thinking and processes and re-draw the mechanics of conducting clinical research based on today’s realities, resources and capabilities
28
How Fast Can We Adapt?
29
US Adoption of EMR/EHR
30
Challenge: Broader Geographies
Accelerating the rate of enrollment in clinical trials toward reduced costs and quicker results
Finding the right patients and navigating narrow inclusion and exclusion criteria
Greater competition for patients and the need for larger sample sizes to detect slight differences
Ethicalconsiderations
RegulatoryOversight
31
Challenge: Registration vs “Real World”
Safety & Efficacy Generalized Safety & Effectiveness
32
Challenge: Access to Patients
Vast cultural differences on healthcare “privacy.” Nordic countries have a tradition of health registries. Every citizen is provided with an identifier from birth and enrolled into registries to elucidate epidemiological trends. Data are used for public health research and improvement of medical care.
Can we guarantee healthcare privacy as we break new ground to accelerate research? Can we generalize across countries?
33
Challenge: Public Image & Understanding
• Imperative to improve patient understanding
• Transparency
• Enlist global patient support groups and disease societies
• Much work is needed
34
Concluding Thoughts
• Healthcare and the global Bio-Pharmaceutical market are undergoing dramatic changes
• Research methods that served us in the past can no longer sustain the industry and today’s ROI models/rates must move to higher levels, and fast
• Bio-Pharma will depend on service providers to innovate and lead transformational changes toward competitiveness, savings, flexibility, global reach, and new insights
• There are many emerging opportunities that can significantly streamline the conduct of clinical research, reduce the burden and complexity, and result in greater efficiency. Focused and deliberate collaboration between regulators, industry and service providers will be key for future advancement
• We must consider dramatic changes in process and bold new structures to transform the industry
• Globalization is here to stay – competition for patients and the need to accelerate trials dictate a worldwide strategy
• Global consensus on privacy issues and access to healthcare data will continue to be the subject of debate. Local, national and cultural differences must be respected. Trust is earned.
• We must educate patients and the general public and provide transparency and access to research information.
THANK YOU!Hani Zaki
[email protected] + 1 215.444.8544